Decoglurant

Last updated
Decoglurant
Decoglurant structure.svg
Clinical data
Other namesRG1578 and RO4995819
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • 5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C21H11F6N5
Molar mass 447.344 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F
  • InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)
  • Key:DMJHZVARRXJSEG-UHFFFAOYSA-N

Decoglurant (INN; development codes RG1578 and RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. [1] [2] Decoglurant progressed as far as phase II clinical trials [1] [2] but was ultimately discontinued from further development due to disappointing efficacy results. [3] [4]

Contents

See also

References

  1. 1 2 "Roche – Pipeline". 2014. Archived from the original on 2022-10-23. Retrieved 2014-08-01.
  2. 1 2 "Roche Group Development Pipeline" (PDF). 2014. Archived from the original (PDF) on 2014-08-08. Retrieved 2014-08-01.
  3. ↑ "Roche – Pipeline" (PDF). 2015. Archived from the original (PDF) on 2015-05-01. Retrieved 2015-05-14.
  4. ↑ Lawrence J (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal. 294 (7854/5).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.